摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-1-(4-chlorophenyl)-3-(3-methoxy-4-(hydroxy)phenyl)prop-2-en-1-one | 152809-69-3

中文名称
——
中文别名
——
英文名称
(E)-1-(4-chlorophenyl)-3-(3-methoxy-4-(hydroxy)phenyl)prop-2-en-1-one
英文别名
(2E)-1-(4-chlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one;(E)-1-(4-chlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one;chalcone 4 hydrate;chalcone-4;4'-chloro-4-hydroxy-3-methoxy-trans-chalcone;4'-Chlor-4-hydroxy-3-methoxy-trans-chalkon;(E)-1-(4'-Chlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
(E)-1-(4-chlorophenyl)-3-(3-methoxy-4-(hydroxy)phenyl)prop-2-en-1-one化学式
CAS
152809-69-3
化学式
C16H13ClO3
mdl
——
分子量
288.73
InChiKey
KCTNGNPVURILGU-KRXBUXKQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    268-270 °C
  • 沸点:
    458.7±45.0 °C(Predicted)
  • 密度:
    1.287±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (E)-1-(4-chlorophenyl)-3-(3-methoxy-4-(hydroxy)phenyl)prop-2-en-1-onepotassium carbonate一水合肼 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 28.0h, 生成 1-(3-(4-Chlorophenyl)-4,5-dihydro-5-(3-methoxy-4-(prop-2-ynyloxy)phenyl)pyrazol-1-yl)ethanone
    参考文献:
    名称:
    通过点击化学合成1,2,3-三唑系留双功能杂化物及其细胞毒性研究
    摘要:
    考虑到目前使用的大多数抗癌药物的耐药性,已合成了吡唑基查耳酮和由三唑环束缚的对硝基苄基官能团的分子杂合物,并评估了其对三种人类癌细胞系(THP,COLO-205)的细胞毒性研究,A-549)。初步研究的结果显示出细胞毒性活性对电子因子的显着依赖性。萘基(JGPT-11)和三甲氧基苯基环(JGPT-6)作为环A的放置被证明对增强细胞毒性潜力极为有利。因此,我们在本文中报道了新型分子杂合体的合成和细胞毒性研究。对JGPT-11和6的生物学机理的详细研究正在进行中。
    DOI:
    10.1007/s00044-012-0312-7
  • 作为产物:
    参考文献:
    名称:
    Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo
    摘要:
    Chalcone 4 (compound 1) is a small molecule that neutralizes the CXC chemokine CXCL12 and prevents it from acting on the CXCR4 and CXCR7 receptors. To overcome its poor solubility in aqueous buffers, we designed highly soluble analogues of compound 1, phosphate, L-seryl, and sulfate, all inactive by themselves on CXCL12 but when cleaved in vivo into 1, highly active locally at a low dose in a mouse airway hypereosinophilia model.
    DOI:
    10.1021/ml200017d
点击查看最新优质反应信息

文献信息

  • [EN] PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES<br/>[FR] DÉRIVÉS DE PYRIMIDINONE ET LEURS UTILISATIONS POUR NEUTRALISER L'ACTIVITÉ BIOLOGIQUE DES CHIMIOKINES
    申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENT - CNRS -
    公开号:WO2018011376A1
    公开(公告)日:2018-01-18
    A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.
    本发明的一个主题是具有通式(I)的化合物,其药学上可接受的盐或其互变异构体,其中A、B3、B4、B5、Y、X、B1和B2如权利要求1至10中的任一所定义。本发明的另一个主题是上述定义的化合物作为药物的用途,特别用于预防和/或治疗炎症和炎症性疾病、免疫和自身免疫疾病、与疼痛有关的疾病、遗传疾病和/或癌症。
  • Synthesis and cdc25B inhibitory activity evaluation of chalcones
    作者:Fei Zhao、Qing-Jie Zhao、Jing-Xia Zhao、Da-Zhi Zhang、Qiu-Ye Wu、Yong-Sheng Jin
    DOI:10.1007/s10600-013-0563-7
    日期:2013.5
    A library of sixty-five chalcones was prepared for screening against the protein phosphatase, cdc25B. From this library, thirteen compounds were found having good inhibitory activity. Two compounds have excellent activity and can be used for the design of more potent antiproliferative agents.
    制备了一个包含六十五种查尔酮的库,用于针对蛋白磷酸酶cdc25B进行筛选。从这个库中,发现了十三种具有良好抑制活性的化合物。其中两种化合物表现出极佳的活性,可用于设计更有效的抗增殖剂。
  • Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans
    作者:D. Batovska、St. Parushev、A. Slavova、V. Bankova、I. Tsvetkova、M. Ninova、H. Najdenski
    DOI:10.1016/j.ejmech.2006.08.012
    日期:2007.1
    A large series of chalcones were synthesized and studied for activity against Candida albicans. The SAR analysis showed that the antifungal activity was highly dependent on the substitution pattern of the aryl rings and correlated to a large extent with the ability of compounds to interact with sulfhydryl groups. The most active were the hydroxylated chalcones as their activity related to the location
    合成了大量查耳酮,并研究了其对白色念珠菌的活性。SAR分析表明,抗真菌活性高度依赖于芳基环的取代方式,并在很大程度上与化合物与巯基相互作用的能力有关。最具活性的是羟基化查耳酮,因为它们的活性与芳基环B中酚基的位置有关,如下所示:o-OH> p-OH约为3,4-di-OH> m-OH。获得的这些相关性和其他相关性极大地有助于设计抗候选查耳酮。
  • Studies on the Laccase‐Catalyzed Oxidation of 4‐Hydroxy‐Chalcones
    作者:Simone Grosso、Fabio Radaelli、Giovanni Fronza、Daniele Passarella、Daniela Monti、Sergio Riva
    DOI:10.1002/adsc.201900190
    日期:——
    The laccase‐catalyzed oxidation of a series of substituted 4‐hydroxy‐chalcones has been investigated. The main isolated dimeric products were, as expected, racemic mixtures of trans‐2,3‐dihydrobenzofuran derivatives, always co‐eluted with an additional isomeric dimer with an open structure. The two enantiomers, as well as the co‐eluted dimeric isomer could be isolated by semi‐preparative HPLC with
    已经研究了漆酶催化的一系列取代的4-羟基查耳酮的氧化。如预期的那样,主要的分离二聚产物是反式-2,3-二氢苯并呋喃衍生物的外消旋混合物,总是与具有开放结构的其他异构二聚体共洗脱。两种对映体以及共洗脱的二聚体异构体可通过半制备型HPLC用手性柱进行分离并进行充分表征。
  • Design, Synthesis, and Docking Study of Pyrimidine-Triazine Hybrids for GABA Estimation in Animal Epilepsy Models
    作者:Meeta Sahu、Nadeem Siddiqui、Mohd. Javed Naim、Ozair Alam、Mohammad Shahar Yar、Vidushi Sharma、Sharad Wakode
    DOI:10.1002/ardp.201700146
    日期:2017.9
    carbamazepine. In the series, 5‐(4‐(4‐fluorophenyl)‐6‐(4‐hydroxyphenyl)‐2‐thioxo‐5,6‐dihydropyrimidin1(2H)‐yl)‐1,2‐dihydro‐1,2,4‐triazin‐3(6H)‐one (4o) and 5‐(6‐(4‐hydroxy‐3‐methoxyphenyl)‐4‐(4‐hydroxyphenyl)‐2‐thioxo‐5,6‐dihydropyrimidin1(2H)‐yl)‐1,2‐dihydro‐1,2,4‐triazin‐3(6H)‐one (4s) emerged as most potent anticonvulsant agents with median doses of 22.54 and 29.40 mg/kg (MES ED50), 285.02 and 293
    设计并合成了一系列新的嘧啶-三嗪杂化物(4a-t),从中鉴定出有效的抗惊厥药。与标准药物苯妥英和卡马西平相比,大多数化合物对最大电休克 (MES) 和皮下戊四唑 (scPTZ) 测试表现出有希望的抗惊厥活性,以及​​最小的运动损伤和更高的安全性。在该系列中,5-(4-(4-fluorophenyl)-6-(4-hydroxyphenyl)-2-thioxo-5,6-dihydropyrimidin-1(2H)-yl)-1,2-dihydro-1,2 ,4-triazin-3(6H)-one (4o) 和 5-(6-(4-羟基-3-甲氧基苯基)-4-(4-羟基苯基)-2-硫代-5,6-二氢嘧啶-1( 2H)-yl)-1,2-dihydro-1,2,4-triazin-3(6H)-one (4s) 成为最有效的抗惊厥药,中位剂量为 22.54 和 29.40 mg/kg (MES ED50),
查看更多